Cite
Lenihan DJ, Anderson SA, Lenneman CG, et al. A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure. JACC Basic Transl Sci. 2016;1(7):576-586doi: 10.1016/j.jacbts.2016.09.005.
Lenihan, D. J., Anderson, S. A., Lenneman, C. G., Brittain, E., Muldowney, J. A. S., Mendes, L., Zhao, P. Z., Iaci, J., Frohwein, S., Zolty, R., Eisen, A., Sawyer, D. B., & Caggiano, A. O. (2016). A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure. JACC. Basic to translational science, 1(7), 576-586. https://doi.org/10.1016/j.jacbts.2016.09.005
Lenihan, Daniel J, et al. "A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure." JACC. Basic to translational science vol. 1,7 (2016): 576-586. doi: https://doi.org/10.1016/j.jacbts.2016.09.005
Lenihan DJ, Anderson SA, Lenneman CG, Brittain E, Muldowney JAS, Mendes L, Zhao PZ, Iaci J, Frohwein S, Zolty R, Eisen A, Sawyer DB, Caggiano AO. A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure. JACC Basic Transl Sci. 2016 Dec 26;1(7):576-586. doi: 10.1016/j.jacbts.2016.09.005. eCollection 2016 Dec. PMID: 30167542; PMCID: PMC6113538.
Copy
Download .nbib